Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase III clinical study of SUN Y7017 Double blind controlled Study for safety evaluation of 1-step titration with 3-step titration in patients with moderate to severe Alzheimer's disease

X
Trial Profile

Phase III clinical study of SUN Y7017 Double blind controlled Study for safety evaluation of 1-step titration with 3-step titration in patients with moderate to severe Alzheimer's disease

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Memantine (Primary)
  • Indications Alzheimer's disease
  • Focus Adverse reactions
  • Sponsors Daiichi Sankyo Company
  • Most Recent Events

    • 29 Aug 2017 Status changed from active, no longer recruiting to completed.
    • 19 Apr 2017 Status changed from not yet recruiting to active, no longer recruiting.
    • 27 May 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top